Search

Displaying results 4771 - 4780 of 7186 in total
  1. Drug

    Dicyclomine

    go.drugbank.com/drugs/DB00804
    ApprovedInvestigational

    Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder … [A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may have been based on a small amount of evidence and so its prescription is becoming less favourable.

  2. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain, to reduce the addictive … TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients.

    Synonyms: TA-NIC
  3. Drug

    Cinitapride

    go.drugbank.com/drugs/DB08810
    Investigational

    Cinitapride is a gastroprokinetic agent and antiulcer benzamide with agonist activity at 5-HT1 and 5-HT4 receptors and antagonist activity at 5-HT2 receptors. It is marketed in Spain and Mexico.

    Synonyms: 4-Amino-N-(1-(3-cyclohexen-1-ylmethyl)-4-piperidyl)-2-ethoxy-5-nitrobenzamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.

  5. Drug

    APL-9

    go.drugbank.com/drugs/DB16460
    Investigational

    APL-9 is an investigational drug intended to centrally control the complement cascade at C3, potentially treating various diseases caused by excessive or uncontrolled complement activation. … It shares the same mechanism of action as Apellis’ lead compound, pegcetacoplan (APL-2), but with a lower molecular weight and shorter half-life.

  6. Drug

    Tenamfetamine

    go.drugbank.com/drugs/DB01509
    IllicitInvestigational

    It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  7. Drug

    Z-Val-Ala-Asp fluoromethyl ketone

    go.drugbank.com/drugs/DB07744
    Experimental

    It does not require an esterase to hydrolyze the O-methyl ester like the cell-permeable form, Z-Val-Ala-Asp(O-Me) fluoromethyl ketone.

    Synonyms: N-[(Benzyloxy)carbonyl]-L-valyl-N-[(2S)-1-carboxy-4-fluoro-3-oxo-2-butanyl]-L-alaninamide, Z-VAD-FMK
  8. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    The vaccine consists of a string of 18 HIV-derived major histocompatibility complex (MHC) Class II restricted epitopes, each separated by a spacer designed to optimize potency. … The vaccine protein is adsorbed to Alhydrogel adjuvant and has been shown to effectively stimulate HTL responses against multiple epitopes in a mouse model.

  9. Drug

    Sulfadiazine

    go.drugbank.com/drugs/DB00359
    ApprovedInvestigationalVet approved

    One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.

    Synonyms: N(1)-2-Pyrimidylsulfanilamide, N(1)-2-Pyrimidinylsulfanilamide
  10. Drug

    Clopamide

    go.drugbank.com/drugs/DB13792
    Investigational

    Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.